Intera Atlas
Run match
Sites / Flourish Research
Is this you?

Request access for Flourish Research with your @flourishresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Flourish Research

Unclaimed profile

Site Network · Apex, NC · ~24 sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 8Lift (cardio sample) 0.29Recruit soph 0.71
Quality Scorecard (1–100)
Overall67Recruit75Ops64Sponsor65Ther64

Performance (observed)

Historical trials
161
Completed
44
Terminated/Withdrawn
11
Completion rate
80%
Active now
106
Phase 2
56
Phase 3
77
Realized enrollment
295,254
First study year
2008
Years active
18
Match confidence
high
Enrollment velocity (inf)
16,403

Therapeutic

Areas
Cardiometabolic, Neuroscience (Alzheimer's), Oncology, Infectious Disease, Vaccines
Specialties
Cardiometabolic, oncology, neuroscience (Alzheimer's focus), infectious disease, vaccines, Phase I/First-in-human
Breadth (conditions)
189
Languages
English + Spanish (detected)
States
Multi-state (AL, CA, FL, GA, IL, LA, MD, MI, MN, MS, NC, NJ, NY, PA, TX, and more)

Recruitment (web observed)

Meta Pixel
Yes
Facebook Ads
Yes
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y - patient-focused content pages
Capability notes
Wholly-owned multi-site network; 150+ investigators; 400,000+ patient database; 100,000+ patients enrolled across studies; best-in-class recruitment experience; top enroller across studies; diverse patient populations; Phase I-IV capabilities including first-in-human and inpatient studies; proven enrollment track record

Relationships

Sponsors
Pfizer; Eli Lilly and Company; Novartis Pharmaceuticals; Amgen; Regeneron Pharmaceuticals; ModernaTX, Inc.
CROs
Crossject; IQVIA Pty Ltd; Novotech (Australia) Pty Limited; Parexel; Premier Research; Worldwide Clinical Trials
Owner / parent
Genstar Capital (majority, acquired Sept 2024), NMS Capital (minority); 274 employees
Funding
VC-backed, acquired by Genstar Capital (Sept 2024)
Acquisitions
Excel Medical Clinical Trials (2021), Diablo Clinical Research (2025)
Expansion
Acquired Diablo Clinical Research (Feb 2025), 10 states coverage
Recent hiring
Y - 26.3% YoY growth (+107 employees)

Capacity & people

Investigators
—
Coordinators
—
CEO
Reinhold Schulz
VP Clinical Ops
Unknown
VP Site Ops
Ana T. Marquez, EVP
VP Recruitment
Brooke Evans, Chief Growth Officer
Emails
checkmann@flourishresearch.com

Tech & DCT

eSource
Yes
Builds tech
Builds tech internally and leverages best-in-class systems
DCT / decentralized
Y - multi-site national network
Tech stack
Best-in-class technology and operations systems mentioned; proprietary patient database and recruitment systems
Recruiting visible
Y

Notes

EXCELLENT Intera fit: PE-backed (Genstar) growth-focused multi-site network with significant recruitment infrastructure. Multiple concurrent studies, proven enrollment track record, large patient database (400K+), diverse therapeutic mix including high-volume areas (cardiometabolic, vaccines). Multiple sites, multiple studies, recruitment-constrained growth model. Leadership focused on growth (Chief Growth Officer). Ideal customer profile for AI patient recruitment platform. Strong acquisition momentum. [Validated: 15 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 1.00Liftability 0.29Overall67

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.